Daphne Karydas - Jun 17, 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc. (LOGC)

Role
Director
Signature
/s/ Andrea Paul, as Attorney-in-Fact
Stock symbol
LOGC
Transactions as of
Jun 17, 2022
Transactions value $
$0
Form type
4
Date filed
7/5/2022, 06:59 AM
Previous filing
Jun 14, 2021
Next filing
Nov 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Stock Option (right to buy) Award $0 +12.5K $0.00 12.5K Jun 17, 2022 Common Stock 12.5K $0.38 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy.
F2 The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.

Remarks:

The Company was not able to timely file due to trouble generating and receiving replacement EDGAR codes.